array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(28) "Bristol-Myers Squibb Company"
["slug"]=>
string(37) "81631-us-bristol-myers-squibb-company"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/7b41874f-2658-484b-890c-9b9bd5a41f13"
["description"]=>
string(1400) "At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.
Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.
Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.
Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html"
["address_street"]=>
string(19) "430 E 29TH St FL 14"
["address_place"]=>
string(8) "New York"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1887-02-28"
["website_domain"]=>
string(7) "bms.com"
["website_url"]=>
string(19) "https://www.bms.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(1200)
["article_count"]=>
int(2495)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(65) "BMS’ Gillett: International division to expand fourfold by 2027"
["snippet_en"]=>
string(70) "The unit will target Northern European M&A within the next six months."
["url"]=>
string(140) "https://www.insuranceinsider.com/article/2d079o0gf79bssxl6dn28/brokers-section/bms-gillett-international-division-to-expand-fourfold-by-2027"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/37b6aba3-3ad0-4327-a396-9ccb0cf4ea1b"
["source"]=>
string(20) "insuranceinsider.com"
["publication_date"]=>
string(10) "2024-03-22"
["categories"]=>
array(4) {
[0]=>
string(19) "Foreign Development"
[1]=>
string(18) "Expansion & Growth"
[2]=>
string(11) "Acquisition"
[3]=>
string(6) "Merger"
}
}
[1]=>
array(7) {
["title_en"]=>
string(103) "'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights"
["snippet_en"]=>
string(116) "Two recent M&A announcements by big pharma are creating excitement among investors. Here's who is poised to benefit."
["url"]=>
string(118) "https://www.cnbc.com/2024/02/19/these-names-may-benefit-amid-increasing-innovation-and-demand-in-neuropsychiatry-.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/56df3084-df3e-4f44-b272-6798735e56af"
["source"]=>
string(8) "cnbc.com"
["publication_date"]=>
string(10) "2024-02-19"
["categories"]=>
array(5) {
[0]=>
string(15) "Deals & Tenders"
[1]=>
string(11) "Acquisition"
[2]=>
string(9) "Investors"
[3]=>
string(6) "Merger"
[4]=>
string(24) "Employee Health & Safety"
}
}
[2]=>
array(7) {
["title_en"]=>
string(60) "BMS launches its M&A division in Spain by signing Linklaters"
["snippet_en"]=>
string(70) "The broker BMS Group has hired Ricardo Lecaro for the launch of its..."
["url"]=>
string(99) "https://www.grupoaseguranza.com/noticias-de-seguros/bms-lanza-division-m-espana-fichando-linklaters"
["image_url"]=>
NULL
["source"]=>
string(19) "grupoaseguranza.com"
["publication_date"]=>
string(10) "2023-11-13"
["categories"]=>
array(4) {
[0]=>
string(6) "Merger"
[1]=>
string(14) "Product Launch"
[2]=>
string(11) "Acquisition"
[3]=>
string(10) "New Market"
}
}
[3]=>
array(7) {
["title_en"]=>
string(66) "$74bn BMS/Celgene merger finally cleared by competition regulators"
["snippet_en"]=>
string(300) "Bristol-Myers Squibb and Celgene’ s merger looks set to close tomorrow after US competition regulators finally gave the$ 74 billion deal the go-ahead.The merger has been given the go-ahead by the Federal Trade Commission, more than ten months after the companies first announced their intentions to"
["url"]=>
string(95) "https://pharmaphorum.com/news/74bn-bms-celgene-merger-finally-cleared-by-competition-regulators"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/60064731-cd94-4ca5-bfa2-6338ae05e38c"
["source"]=>
string(16) "pharmaphorum.com"
["publication_date"]=>
string(10) "2023-08-25"
["categories"]=>
array(2) {
[0]=>
string(6) "Merger"
[1]=>
string(11) "Competition"
}
}
[4]=>
array(7) {
["title_en"]=>
string(58) "Therapeutics Co. Sued Ahead of Bristol-Myers Squibb Merger"
["snippet_en"]=>
string(153) "Michael Kent, a shareholder, has filed a complaint against Turning Point Therapeutics, Inc and its board of directors seeking both an injunction and more"
["url"]=>
string(97) "https://lawstreetmedia.com/news/health/therapeutics-co-sued-ahead-of-bristol-myers-squibb-merger/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/be1ab708-2f1c-4ccd-9373-e1c5fca0b1a9"
["source"]=>
string(18) "lawstreetmedia.com"
["publication_date"]=>
string(10) "2022-07-07"
["categories"]=>
array(2) {
[0]=>
string(6) "Merger"
[1]=>
string(10) "Complaints"
}
}
[5]=>
array(7) {
["title_en"]=>
string(93) "Bristol Myers loses bid to toss $6.4B CVR lawsuit tied to Celgene takeover, Breyanzi approval"
["snippet_en"]=>
string(299) "A U.S. federal court on Friday shot down Bristol Myers Squibb’s motion to dismiss an investor lawsuit connected to its $74 billion Celgene buyout. | A U.S. federal court on Friday shot down Bristol Myers Squibb’s motion to dismiss an investor lawsuit connected to its $74 billion Celgene buyout."
["url"]=>
string(127) "https://www.fiercepharma.com/pharma/bristol-myers-loses-bid-toss-64-billion-cvr-lawsuit-tied-celgene-takeover-breyanzi-approval"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/46beea6c-c793-4a33-8141-aea42228d98c"
["source"]=>
string(16) "fiercepharma.com"
["publication_date"]=>
string(10) "2022-06-27"
["categories"]=>
array(4) {
[0]=>
string(6) "Merger"
[1]=>
string(11) "Acquisition"
[2]=>
string(10) "Misconduct"
[3]=>
string(5) "Legal"
}
}
[6]=>
array(7) {
["title_en"]=>
string(58) "Why Are Bristol-Myers & Turning Point Made for Each Other?"
["snippet_en"]=>
string(209) "Bristol-Myers Squibb Company (NYSE: BMY) is all set to merge Turning Point Therapeutics, Inc. (NASDAQ: TPTX), an oncology company, into its portfolio. A definitive merger agreement has been signed between the"
["url"]=>
string(86) "https://www.tipranks.com/news/why-are-bristol-myers-turning-point-made-for-each-other/"
["image_url"]=>
string(105) "https://businessradar-prod-article-images.s3-eu-west-1.amazonaws.com/9b891176-3652-488b-a086-9bc6cbebd5af"
["source"]=>
string(12) "tipranks.com"
["publication_date"]=>
string(10) "2022-06-06"
["categories"]=>
array(2) {
[0]=>
string(6) "Merger"
[1]=>
string(21) "Competitive Behaviour"
}
}
[7]=>
array(7) {
["title_en"]=>
string(65) "The ecosystem overtakes the producers in pharma and life sciences"
["snippet_en"]=>
string(33) "M&A returns – but in a new form"
["url"]=>
string(121) "https://www.pharmatimes.com/magazine/2021/december_2021/the_ecosystem_overtakes_the_producers_in_pharma_and_life_sciences"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/79e191af-09e1-4694-9821-f935e1cd5a54"
["source"]=>
string(15) "pharmatimes.com"
["publication_date"]=>
string(10) "2021-12-01"
["categories"]=>
array(2) {
[0]=>
string(6) "Merger"
[1]=>
string(11) "Acquisition"
}
}
[8]=>
array(7) {
["title_en"]=>
string(79) "SM Merger/Arbitrage, L.P. et al v. Bristol-Myers Squibb Comp... | Law.com Radar"
["snippet_en"]=>
string(63) "DLA Piper partner John J. Clarke Jr. has entered an appearan..."
["url"]=>
string(108) "https://www.law.com/radar/card/sm-merger-arbitrage-lp-et-al-v-bristol-myers-squibb-company-et-al-42157319-1/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/141a23ea-388a-4b2b-82c1-89466463c762"
["source"]=>
string(7) "law.com"
["publication_date"]=>
string(10) "2021-10-06"
["categories"]=>
array(2) {
[0]=>
string(10) "Litigation"
[1]=>
string(6) "Merger"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(254)
}
[1]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(163)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(151)
}
[3]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(94)
}
[4]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(89)
}
[5]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(76)
}
[6]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(74)
}
[7]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(64)
}
[8]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(63)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(60)
}
[10]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(60)
}
[11]=>
array(2) {
["name"]=>
string(17) "Energy Management"
["count"]=>
int(56)
}
[12]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(54)
}
[13]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(47)
}
[14]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(47)
}
[15]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(45)
}
[16]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(45)
}
[17]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(42)
}
[18]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(39)
}
[19]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(35)
}
[20]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[21]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(33)
}
[22]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(32)
}
[23]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(28)
}
[24]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(22)
}
[28]=>
array(2) {
["name"]=>
string(9) "Valuation"
["count"]=>
int(21)
}
[29]=>
array(2) {
["name"]=>
string(15) "Blogs & Columns"
["count"]=>
int(21)
}
}
}
81631-us-bristol-myers-squibb-company
Bristol-Myers Squibb Company
Location
New York
Founded
1887-02-28
Website
https://www.bms.com
Articles
2495 Articles
Category
Pharmaceutical Preparations
Description
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.
Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.
Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.
Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
Bristol-Myers Squibb and Celgene’ s merger looks set to close tomorrow after US competition regulators finally gave the$ 74 billion deal the go-ahead.The merger has been given the go-ahead by the Federal Trade Commission, more than ten months after the companies first announced their intentions to
Michael Kent, a shareholder, has filed a complaint against Turning Point Therapeutics, Inc and its board of directors seeking both an injunction and more
A U.S. federal court on Friday shot down Bristol Myers Squibb’s motion to dismiss an investor lawsuit connected to its $74 billion Celgene buyout. | A U.S. federal court on Friday shot down Bristol Myers Squibb’s motion to dismiss an investor lawsuit connected to its $74 billion Celgene buyout.
Bristol-Myers Squibb Company (NYSE: BMY) is all set to merge Turning Point Therapeutics, Inc. (NASDAQ: TPTX), an oncology company, into its portfolio. A definitive merger agreement has been signed between the
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
